Amberstone Biosciences, Inc.
High-throughput single-cell functional screening platform for bispecific antibody discovery
- Sector
- Biotech
- Headquarters
- LAGUNA HILLS, CA
- Latest Form D
- $6M, Dec 2021
- Total capital
- $8.4M
- Federal grants
- $2.4M
- 4 awards · 2019–2021
- Rank in peer group#15 of 37
- Private capital raised
- $6M
- 1 Form D · last Dec 2021
- 58 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 13 pending · first 2021
- Rank in peer group#5 of 37
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$6M
- Federal grantNSF · Phase II · SBIR Phase II: A single-cell-interaction platform for accelerating discovery of bispecific antibodies$1.5M
- Federal grantHealth and Human S · Phase I · Discovery of broad-spectrum, cross-neutralizing bispecific antibodies against SARS-CoV-2 using high throughput functional screening$300K
- Federal grantHealth and Human S · Phase I · Discovery of broad-spectrum, cross-neutralizing bispecific antibodies against SARS-CoV-2 using high throughput functional screening$300K
- Federal grantNSF · Phase I · SBIR Phase I: A single-cell-interaction platform for accelerating discovery of bispecific T-cell engagers$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
30months
from Amberstone Biosciences, Inc.’s first federal award to its first private round.
- First federal award · Jul 2019
- NSF · $225K
- First Form D · Dec 2021
- $6M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 37 peers
Line = medianBiotech · Platform
- Federal grants#15 · top 41%
- Granted patents#5 · top 14%
- Linked publications#1 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Yonglei Guikai ShangResearcherExecutive Officer, DirectorLinked by 1 patent
- George Guikai WuResearcherExecutive Officer, DirectorLinked by $1.8M in grants as PI
- Weian Guikai ZhaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 18- GrantedCompartmentalized Assays Of Bispecific And Multispecific BiologicsUSPTOUS 12,510,535
- GrantedANTI-CD3 Constructs And Uses ThereofUSPTOUS 12,227,574
- GrantedCompartmentalized Assays Of Bispecific And Multispecific BiologicsUSPTOUS 11,913,939
Show all 18 patent records
- Compartmentalized Assays Of Bispecific And Multispecific BiologicsDec 30, 2025 · US 12,510,535Granted
- ANTI-CD3 Constructs And Uses ThereofFeb 18, 2025 · US 12,227,574Granted
- Compartmentalized Assays Of Bispecific And Multispecific BiologicsFeb 27, 2024 · US 11,913,939Granted
- Microfluidic Determination Of Heterogeneous ObjectsDec 7, 2023 · Application 18328685Pending
- Microfluidic Determination Of Low Abundance EventsDec 30, 2021 · Application 17339540Pending
- Microfluidic Determination Of Low Abundance EventsJul 13, 2021 · US 11,059,044Granted
- Microfluidic Determination Of Low Abundance EventsMar 30, 2021 · US 10,960,394Granted
- Compartmentalized Assays Of Bispecific And Multispecific BiologicsApplication PCTUS2019055047Pending
- Microfluidic Determination Of Low Abundance EventsApplication 62855734Pending
- Compartmentalized Assays Of Bispecific And Multispecific BiologicsApplication 62784171Pending
- ANTI-CD3 Constructs And Uses ThereofApplication PCTUS2025032734Pending
- Compartmentalized Assays Of Bispecific And Multispecific BiologicsApplication 62742837Pending
- ANTI-CD3 Constructs And Uses ThereofApplication 63658312Pending
- ANTI-CD3 Constructs And Uses ThereofApplication PCTUS2022072996Pending
- Microfluidic Determination Of Heterogeneous ObjectsApplication PCTUS2021061440Pending
- ANTI-CD3 Constructs And Uses ThereofApplication 63212024Pending
- Microfluidic Determination Of Heterogeneous ObjectsApplication 63120384Pending
- Microfluidic Determination Of Low Abundance EventsApplication PCTUS2020035340Pending
Recent research by its founders
- Prostaglandin E2 alleviates acetaminophen-induced liver injury through DDIT4-enhanced autophagy regulated by circLima1/miR-48620260 cites
- Co‑treatment with triptolide and RSL3 induces hepatocellular carcinoma cell apoptosis and ferroptosis20258 cites
- Advancements in Pathogen Detection: Argonaute-Based Nucleic Acid Detection Technology20255 cites
Related companies, and why
- AMBERSTONE BIOSCIENCES INCShares a founder: Guikai Wu
- Ironfist Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Eyebiotech LtdSimilar federal contract value in Biotech · null in contracts
- RevOpsis Holdings LLCSimilar federal contract value in Biotech · null in contracts
- GRO BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
- Sangamo TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .